IBD new medication studies

Information about current studies recruiting patients:

Crohn's 1

Crohn's 2

Ulcerative Colitis 1

Ulcerative Colitis 2

Ulcerative Colitis 3

Crohn's 3

Principal investigator:  

Atilla Ertan, MD

Study Coordinator and to apply to enter study

Inci Ertan, PhD, 713-794-0001, ieertan@tmh.tmc.edu , Fax: 713-793-7661


6560 Fannin Street, Suite 2208,   Houston, Texas 77030 United States


  • Crohn's 1
    Quick SummaryStudy #1 Oral Inflabloc Cap -- Clinical trial in patients with moderately active Crohn's disease

    Date PostedDate Posted: 2005-03-10

    InformationThe purpose of this research study is to determine if the oral, investigational drug Inflabloc Cap can safely and effectively reduce the signs and symptoms of moderately active Crohn's disease.
    About Inflabloc Cap
    Inflabloc Cap contains dehydroepiandrosterone, also known as DHEA. DHEA reduces the production of various substances that cause inflammation. An animal model has shown that DHEA reduces inflammation in the bowel. Inflabloc Cap is a capsule taken orally twice daily.

    For more information:



  • Crohn's 2
    Quick SummaryAn Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Crohn's Disease

    Date PostedStudy start: January 2005

    InformationThe purpose of this study is to evaluate the efficacy and safety of Inflabloc Cap (Dehydroepiandrosterone [DHEA]) in the treatment of patients with moderately active Crohn's disease.
    Condition Intervention Phase
    Crohn's Disease Drug: Dehydroepiandrosterone [DHEA] Phase II

For more information:


  • ulcerative colitis 1
    Quick SummaryNO MORE UC - A research study for adults with mild to moderate ulcerative colitis currently in remission

    Date Posted   2005-02-17

    InformationWe are seeking participants for a clinical study to test the safety and effectiveness of encapsulated mesalamine pellets, an investigational medication, for maintenance of remission from mild to moderate ulcerative colitis. The study is comparing the investigational medication to placebo in people who been diagnosed with ulcerative colitis that is in remission. For more information:


  • ulcerative colitis 2

“A Phase 3, Muliticenter, Randomized, Stratified, Double-blind, Placebo-controlled, Parallel-arm, Dose Comparison of the Efficacy and Safety of OPC-6535 tablets in the Treatment soft Patients with active Ulcerative Colitis”

  • ulcerative colitis 3

“Remicade Safety under Long Term Study in Ulcerative Colitis”  (Results-UC)   5 years long follow-up study (continuation of ACT2)

  • Crohn's 3

“A Phase III, Multi-national, Multi-center, Double-blind, Placebo=controlled, Parallel group, 25 week study to assess the Safety and Efficacy of the Humanized anti-TNF PEG conjugate, CDP870, 400 mg sc, (dosed at weeks 0, 2, 4,then 4-weekly to week 24) in the Treatment of Patients with Active Crohn’s Disease”    Subcutaneous injections at weeks 0,2,4,6,8,12,16,20,and 24.

Promising News about Crohn’s disease drugs